NASDAQ:ARDS Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range$0.00▼$0.0852-Week Range N/AVolumeN/AAverage Volume148,192 shsMarket Capitalization$530,000.00P/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends Get Aridis Pharmaceuticals alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. ARDS Stock News HeadlinesJune 24, 2024 | globenewswire.comAridis Provides Corporate UpdateMarch 14, 2024 | uk.investing.comAridis Pharmaceuticals Inc (ARDS)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 10, 2024 | bbc.co.ukIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestDecember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024November 3, 2023 | markets.businessinsider.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 1, 2023 | morningstar.comAridis Pharmaceuticals Inc ARDSJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.October 22, 2023 | benzinga.comAridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, PredictionsOctober 21, 2023 | msn.comHC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy RecommendationOctober 20, 2023 | markets.businessinsider.comFDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy RecommendationSeptember 15, 2023 | finance.yahoo.comARDS Sep 2023 2.500 callSeptember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TVAugust 21, 2023 | investing.comAridis Pharma (ARDS) Earnings Dates & ReportsAugust 2, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces $2 Million OfferingJuly 18, 2023 | finance.yahoo.comWhy Are Aridis Pharmaceuticals Shares Moving Higher Today?July 17, 2023 | finance.yahoo.comAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301See More Headlines Receive ARDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARDS CUSIPN/A CIK1614067 Webwww.aridispharma.com Phone(408) 385-1742Fax408-960-3822Employees37Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.09 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.16) per share Price / BookN/AMiscellaneous Outstanding Shares53,320,000Free Float50,388,000Market Cap$530,000.00 OptionableNot Optionable Beta1.06 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Eric J. Patzer Ph.D. (Age 75)Founder & Executive Chairman Comp: $240kDr. Vu L. Truong Ph.D. (Age 60)Founder, CEO, Chief Scientific Officer & Director Comp: $631.65kDr. Hasan Jafri M.D. (Age 57)Chief Medical Officer Comp: $559.36kMs. Tamara S. Allen (Age 57)Vice President of Finance Mr. Jeffrey J. Fessler Esq. (Age 61)J.D., Acting General Counsel Key CompetitorsAthersysNASDAQ:ATHXCalithera BiosciencesNASDAQ:CALAAmpio PharmaceuticalsNYSE:AMPELucy Scientific DiscoveryNASDAQ:LSDIStatera BiopharmaNASDAQ:STABView All Competitors ARDS Stock Analysis - Frequently Asked Questions How were Aridis Pharmaceuticals' earnings last quarter? Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) issued its earnings results on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The company earned $0.52 million during the quarter. When did Aridis Pharmaceuticals IPO? Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers. How do I buy shares of Aridis Pharmaceuticals? Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aridis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Gilead Sciences (GILD). This page (NASDAQ:ARDS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.